Taksta: Ph III data

Top-line data from 716 ABSSSI patients in the ITT population of a double-blind, U.S. Phase III trial showed that oral Taksta met the primary endpoint of non-inferiority to oral linezolid in early clinical response rate (87.2% vs. 86.6%). The bounds of the 95% confidence interval were 4.6 and 5.9, meeting the 10% non-inferiority margin defined for the primary endpoint.

Taksta also showed comparable efficacy to linezolid in clinical success rates at the end of 10 days of treatment (91.9% vs. 89.6%) and at the post-treatment evaluation 7-14 days later (88.6% vs. 88.5%)...